Latest Development Programs News

Aurum Resources has reported multiple high-grade gold intercepts from its extensive drilling program at the Boundiali Gold Project in Côte d'Ivoire, underpinning plans for aggressive resource growth and a Pre-Feasibility Study in 2026.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Ballymore Resources has reported its richest drill intersection yet at the Torpy’s prospect near Chillagoe, Queensland, revealing exceptionally high-grade silver, lead, zinc, and indium mineralisation. This breakthrough highlights the growing potential of the Torpy’s area and sets the stage for further exploration in 2026.

Great Dirt Resources has confirmed high-grade manganese mineralisation in NSW and identified 24 new exploration targets through advanced R&D techniques, supported by a $315k tax rebate and a strong cash position.

Firebird Metals has commissioned its proprietary equipment for producing advanced lithium-manganese-rich cathode materials at its China pilot plant, aiming to start production in February 2026 with customer samples planned for later in the year. The project is co-funded by strategic partner Taza Metal Technologies, reducing capital risk and accelerating development.

St George Mining reports exceptional drilling results at its Araxá Rare Earths and Niobium Project, significantly expanding its resource footprint, alongside a successful $72.5 million capital raise to fund ongoing development.

InhaleRx Limited has completed the final tranche of its share placement, raising $600,000 to support its clinical-stage drug development programs targeting pain and mental health.

Hydrix Limited’s subsidiary has landed a significant A$2.5 million contract to develop SynCardia’s next-generation fully implantable Total Artificial Heart, marking a major step in advanced cardiovascular technology.

Adisyn Ltd has successfully demonstrated low-temperature deposition of an sp²-based carbon layer using Atomic Layer Deposition, a milestone independently verified and critical for semiconductor integration.

AnteoTech secures a significant order from the Serum Institute of India and expands its Life Sciences pipeline with new product developments and global partnerships, positioning for accelerated growth in 2026.

Clarity Pharmaceuticals’ novel diagnostic agent Cu-SAR-bisPSMA has been selected for oral presentation at the prestigious European Association of Urology Congress 2026, following promising Phase II trial results demonstrating superior detection of prostate cancer recurrence.

Kalamazoo Resources has raised $8 million through a placement and launched a $2 million share purchase plan, aiming to fuel exploration and development across its gold projects.